Archive for August 15th, 2022

Steven R. Gerbsman, Principal of Gerbsman Partners is pleased to announce that Dr. Steven. B. Heymsfield has joined Gerbsman Partners Board of Intellectual Capital. 

Dr. Heymsfield is an International Life Science, BioTech Professional and Educator.  Dr. Heymsfield will provide to Gerbsman Partners and its clients significant domain expertise and access to national and international companies.

Please see below information on Dr. Heymsfield and his significant bibliography of published papers.

Dr. Steven B. Heymsfield, M.D. – International Life Science, BioTech Professional & Educator

Dr. Steven B. Heymsfield, M.D.  is Professor and Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center of the Louisiana State University System in Baton Rouge. He is on the visiting faculty at Harvard Medical School and a former Professor of Medicine at Columbia University, College of Physicians and Surgeons. Prior to Pennington, he was Global Director of Scientific Affairs for the Obesity Group at Merck & Co. 

Dr. Heymsfield has published more than 700 peer-reviewed papers covering topics such as obesity, malnutrition, cancer, cachexia, body composition, and caloric expenditure. His contributions to the study of human nutrition led to the TOPS Award from The Obesity Society (TOS), the Rhoads Award from the American Society of Parenteral and Enteral Nutrition (ASPEN), the Robert H. Herman Memorial Award, American Society of Nutrition (ASN), and the George Bray Founders Award from TOS.  During the President Bush’s Administration he was considered for the Office of the Surgeon General.

Dr. Heymsfield is past president of ASPEN, ASN and TOS. He was recently appointed as an Amazon Scholar and works on the Amazon HALO product.

Please see below Dr. Heymsfield Bibliography from the National Library of Medicine, NIH National Center for Biotechnology Information.


About Gerbsman Partners

Gerbsman Partners focuses on maximizing enterprise value for stakeholders and shareholders in underperforming, undercapitalized and undervalued companies and their intellectual properties. Since 2001, Gerbsman Partners has successfully maximized the values of 116 companies in a wide and diverse spectrum of industries, including technology, software, life science, medical device, biotechnology, etc.  In the process, GP has successfully restructured/terminated over $810 million of real estate executor contracts and equipment lease/sub-debt obligations, and has assisted in over $2.3 billion of financings, restructurings and M&A transactions.

Gerbsman Partners has offices and strategic alliances in Boston, New York, Washington DC, McLean VA, San Francisco, Miami, Orange County, Europe and Israel. 

Read Full Post »